ArticleJournal of medical virology2020
Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis.
Article in Journal of medical virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 868 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Commerical Antibody Tests for COVID-19
Prevalence and Risk Factors of COVID-19 Infection in the Upper Silesian Agglomeration Population in 2020
Who cites it
868 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,882 citations in OpenAlex.
- Association Between Rapid Antigen Detection Tests and Real-Time Reverse Transcription-Polymerase Chain Reaction Assay for SARS-CoV-2: A Systematic Review and Meta-Analyses.International journal of public health · 2023Pooled it
- Antibody tests for identification of current and past infection with SARS-CoV-2.The Cochrane database of systematic reviews · 2022Pooled it
- Evaluation of CRISPR-Based Assays for Rapid Detection of SARS-CoV-2: A Systematic Review and Meta-Analysis.Yonsei medical journal · 2022Pooled it
- Diagnostic utility of antigen detection rapid diagnostic tests for Covid-19: a systematic review and meta-analysis.Diagnostic pathology · 2022Pooled it
- Updating the use of nano-biosensors as promising devices for the diagnosis of coronavirus family members: A systematic review.Journal of pharmaceutical and biomedical analysis · 2022Pooled it
- Gut microbial allies and adversaries in SARS-CoV-2 infection.Current research in microbial sciences · 2026Article
- Performance of Three Commercial Rapid Diagnostic Tests for Detection of IgM and IgG Antibodies Against SARS-CoV-2.Immunity, inflammation and disease · 2026Article
- A quantum dots dual immunochromatography strip for differential detection of high and low virulence ASFV antibodies.Microbiology spectrum · 2026Article
- A Novel Adaptive Platform for Rapid, Simple Flow-Based Antibody Detection Devices Predicts NAb Levels to SARS-CoV-2.Pathogens & immunity · 2026Article
- Article
- Development and clinical application of a rapid qPCR instrument featuring three independent temperature modules and a time-based algorithm for respiratory pathogen diagnosis.Virology journal · 2025Article
- Advances in Point-of-Care Infectious Disease Diagnostics: Integration of Technologies, Validation, Artificial Intelligence, and Regulatory Oversight.Diagnostics (Basel, Switzerland) · 2025Review
- Revolutionizing healthcare with nanosensor technology.RSC advances · 2025Review
- Article
- Rapid SNP genotyping detection method based on PCR-lateral flow dipstick detection technique.Scientific reports · 2025Article
- Ultra-fast, palm-sized platform for visual point-of-care virus detection using convective PCR with gold nanoparticle probes.Mikrochimica acta · 2025Article
- Kalman Filter-Based Epidemiological Model for Post-COVID-19 Era Surveillance and Prediction.Sensors (Basel, Switzerland) · 2025Article
- Emerging Trends of Gold Nanostructures for Point-of-Care Biosensor-Based Detection of COVID-19.Molecular biotechnology · 2025Review
- Advances in Virus Biorecognition and Detection Techniques for the Surveillance and Prevention of Infectious Diseases.Biosensors · 2025Review
- One-Step Immunoassay for Biomarker Quantification in Complex Mixtures Based on Phase-Separated Antifouling Coacervates.Analytical chemistry · 2025Article
808 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outbreak of the novel coronavirus disease (COVID-19) quickly spread all over China and to more than 20 other countries. Although the virus (severe acute respiratory syndrome coronavirus [SARS-Cov-2]) nucleic acid real-time polymerase chain reaction (PCR) test has become the standard method for diagnosis of SARS-CoV-2 infection, these real-time PCR test kits have many limitations. In addition, high false-negative rates were reported. There is an urgent need for an accurate and rapid test method to quickly identify a large number of infected patients and asymptomatic carriers to prevent virus transmission and assure timely treatment of patients. We have developed a rapid and simple point-of-care lateral flow immunoassay that can detect immunoglobulin M (IgM) and IgG antibodies simultaneously against SARS-CoV-2 virus in human blood within 15 minutes which can detect patients at different infection stages. With this test kit, we carried out clinical studies to validate its clinical efficacy uses. The clinical detection sensitivity and specificity of this test were measured using blood samples collected from 397 PCR confirmed COVID-19 patients and 128 negative patients at eight different clinical sites. The overall testing sensitivity was 88.66% and specificity was 90.63%. In addition, we evaluated clinical diagnosis results obtained from different types of venous and fingerstick blood samples. The results indicated great detection consistency among samples from fingerstick blood, serum and plasma of venous blood. The IgM-IgG combined assay has better utility and sensitivity compared with a single IgM or IgG test. It can be used for the rapid screening of SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals, clinics, and test laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.